Frank Rimerman Advisors LLC Purchases 14,228 Shares of Danaher Co. (NYSE:DHR)

Frank Rimerman Advisors LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 638.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 16,457 shares of the conglomerate’s stock after acquiring an additional 14,228 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Danaher were worth $4,112,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. bought a new position in Danaher during the fourth quarter worth about $25,000. Tsfg LLC boosted its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. purchased a new position in Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in Danaher during the 2nd quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher during the first quarter worth $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.4 %

DHR opened at $272.63 on Friday. The business’s fifty day simple moving average is $267.62 and its 200 day simple moving average is $257.16. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a market cap of $201.93 billion, a PE ratio of 46.21, a P/E/G ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $2.05 EPS. As a group, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DHR shares. TD Cowen lifted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Stifel Nicolaus upped their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Barclays increased their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Leerink Partners boosted their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI lowered their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.